Development of inhibitory antibodies in hemophilia A and B remains a major complication in the management of patients, jeopardizing the outcome of treatment. The ultimate goal should be tolerization towards the deficient factor by immune tolerance induction (ITI) therapy. This procedure is however often complex and associated with several issues. This international course highlights the latest knowledge, current challenges of ITI treatment and different therapeutic options – in an era of new potential approaches to assure the best care of patients who have developed inhibitors.

The course is based on lectures and interactive authentic case studies in accordance with case methodology.

Target group: Physicians treating hemophilia. Participants should have previous ITI experience. Good English skills are required.

The course is sponsored by Octapharma and provided by Lund University and the Malmö Centre for Thrombosis and Haemostasis at Skåne University Hospital in collaboration with international hemophilia experts.

For more information please visit: https://www.med.lu.se/translationell_medicin/koagulationsforskning/utbildning or contact Camilla Månsson: camilla.mansson@med.lu.se - phone: +46 (0) 40-33 32 02

Lund University l Clinical Coagulation Research Unit l Jan Waldenströms gata 14 l SE-205 02 Malmö l Sweden